Actively Recruiting
A Study With CIT-013 in RA Patients
Led by Citryll BV · Updated on 2026-03-25
88
Participants Needed
24
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA. Participants will: Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
CONDITIONS
Official Title
A Study With CIT-013 in RA Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients diagnosed with rheumatoid arthritis according to 2010 ACR and EULAR criteria for at least 3 months
- Age between 18 and 85 years
- Disease Activity Score (DAS28-CRP) of 3.2 or higher with at least 3 swollen joints and 3 tender joints, and elevated CRP at screening and before randomization
- Stable treatment with a conventional synthetic disease modifying antirheumatic drug for at least 4 weeks, with use for at least 3 months prior to screening
You will not qualify if you...
- Need for immediate start of biological or targeted synthetic DMARD due to high disease activity or severity
- Contraindication to CIT-013
- Presence of current inflammatory joint disease other than rheumatoid arthritis (excluding Sjogren's with active disease)
- Insufficient washout period from previous biological or targeted synthetic DMARDs, varying from 1 week to 6 months depending on the drug
- Treatment with three or more biological or targeted synthetic DMARDs
- Use of injectable corticosteroids or oral prednisolone over 10 mg/day within 4 weeks before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
BE-02
Antwerp, Belgium
Not Yet Recruiting
2
Site BE-01
Leuven, Belgium
Actively Recruiting
3
DE-04
Bamberg, Germany
Actively Recruiting
4
DE-05
Berlin, Germany
Actively Recruiting
5
DE-01
München, Germany
Not Yet Recruiting
6
DE-02
München, Germany
Actively Recruiting
7
DE-03
Ratingen, Germany
Actively Recruiting
8
NL-02
Amsterdam, Netherlands
Actively Recruiting
9
NL-05
Leeuwarden, Netherlands
Actively Recruiting
10
NL-04
Leiden, Netherlands
Withdrawn
11
NL-03
Nijmegen, Netherlands
Not Yet Recruiting
12
NL-01
Rotterdam, Netherlands
Actively Recruiting
13
PL-01
Bialystok, Poland
Actively Recruiting
14
PL-07
Krakow, Poland
Actively Recruiting
15
PL-03
Lublin, Poland
Actively Recruiting
16
PL-02
Poznan, Poland
Actively Recruiting
17
PL-05
Torun, Poland
Actively Recruiting
18
PL-04
Warsaw, Poland
Actively Recruiting
19
ES-02
A Coruña, Spain
Actively Recruiting
20
ES-04
Barcelona, Spain
Actively Recruiting
21
ES-05
Barcelona, Spain
Not Yet Recruiting
22
ES-06
Madrid, Spain
Actively Recruiting
23
ES-01
Santander, Spain
Not Yet Recruiting
24
ES-03
Santiago de Compostela, Spain
Actively Recruiting
Research Team
L
Leonie Middelink
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here